In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa | Zendy

J Downs | Zendy; Vincent T. Andriole | Zendy; J L Ryan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa

Author(s) -

J Downs,

Vincent T. Andriole,

J L Ryan

Publication year - 1982

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.21.4.670

Subject(s) - carbenicillin , nalidixic acid , serratia marcescens , gentamicin , microbiology and biotechnology , pseudomonas aeruginosa , ampicillin , serratia , trimethoprim , minimum inhibitory concentration , aminoglycoside , antibiotics , tetracycline , escherichia coli , biology , chemistry , bacteria , pseudomonas , biochemistry , genetics , gene

MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. This new agent was more active than any of the other antibiotics tested, which included carbenicillin, ampicillin, cephalexin, tetracycline, trimethoprim, trimethoprim-sulfamethoxazole, and nalidixic acid. Gentamicin-resistant P. aeruginosa were highly sensitive to MK-0366, with a 90% minimal inhibitory concentration of 0.8 microgram/ml. Serratia strains were the most resistant organisms, with a 90% minimal inhibitory concentration of 3.1 micrograms/ml. These results suggest that clinical trials should be designed to investigate the clinical usefulness of this new drug in urinary infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research